Silvia Borriello, Umberto Santaniello, Matteo G Brizio, Paolo Fava, Giovanni Cavaliere, Giulia Carpentieri, Rebecca Senetta, Adriana Lesca, Simone Ribero, Pietro Quaglino, Franco Picciotto
{"title":"Synchronous Melanoma and Follicular Lymphoma in the Same Nodal Basin: A Diagnostic and Therapeutic Challenge.","authors":"Silvia Borriello, Umberto Santaniello, Matteo G Brizio, Paolo Fava, Giovanni Cavaliere, Giulia Carpentieri, Rebecca Senetta, Adriana Lesca, Simone Ribero, Pietro Quaglino, Franco Picciotto","doi":"10.1002/cnr2.70363","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The incidence of both malignant melanoma (MM) and non-Hodgkin lymphoma (NHL) has risen in recent decades, with studies suggesting a potential bidirectional association. Nonetheless, synchronous presentation of active disease in both entities remains rare.</p><p><strong>Case: </strong>We report the case of a 62-year-old man with a history of indolent B-cell lymphoma, exhibiting features between marginal zone and follicular subtype, previously treated with R-CHOP, radiotherapy, and Rituximab maintenance, achieving complete remission. Ten years later, he developed an ulcerated superficial spreading melanoma (Breslow thickness 4.5 mm, pT4b), with staging CT revealing right axillary lymphadenopathy. Biopsy confirmed relapsed follicular lymphoma. Surgical management included wide excision and sentinel lymph node biopsy, which identified melanoma metastasis in one sentinel node and confirmed FL in the non-sentinel node. Molecular testing showed a BRAFV600E mutation. The patient received axillary radiotherapy followed by adjuvant BRAF/MEK inhibitor therapy.</p><p><strong>Conclusion: </strong>At 6-month follow-up, imaging showed no evidence of relapse. This represents the first documented case of synchronous stage III BRAF-mutated MM and FL managed with targeted BRAF/MEK inhibitors combined with localized radiotherapy. The successful outcome validates this sequential multidisciplinary approach and underscores the importance of dermatologic surveillance in NHL survivors.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":"e70363"},"PeriodicalIF":1.9000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/cnr2.70363","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The incidence of both malignant melanoma (MM) and non-Hodgkin lymphoma (NHL) has risen in recent decades, with studies suggesting a potential bidirectional association. Nonetheless, synchronous presentation of active disease in both entities remains rare.
Case: We report the case of a 62-year-old man with a history of indolent B-cell lymphoma, exhibiting features between marginal zone and follicular subtype, previously treated with R-CHOP, radiotherapy, and Rituximab maintenance, achieving complete remission. Ten years later, he developed an ulcerated superficial spreading melanoma (Breslow thickness 4.5 mm, pT4b), with staging CT revealing right axillary lymphadenopathy. Biopsy confirmed relapsed follicular lymphoma. Surgical management included wide excision and sentinel lymph node biopsy, which identified melanoma metastasis in one sentinel node and confirmed FL in the non-sentinel node. Molecular testing showed a BRAFV600E mutation. The patient received axillary radiotherapy followed by adjuvant BRAF/MEK inhibitor therapy.
Conclusion: At 6-month follow-up, imaging showed no evidence of relapse. This represents the first documented case of synchronous stage III BRAF-mutated MM and FL managed with targeted BRAF/MEK inhibitors combined with localized radiotherapy. The successful outcome validates this sequential multidisciplinary approach and underscores the importance of dermatologic surveillance in NHL survivors.
背景:近几十年来,恶性黑色素瘤(MM)和非霍奇金淋巴瘤(NHL)的发病率都有所上升,研究表明两者之间存在潜在的双向关联。尽管如此,在两个实体中同时出现活动性疾病仍然很少见。病例:我们报告一例62岁男性无性b细胞淋巴瘤病史,表现出介于边缘区和滤泡亚型之间的特征,先前接受R-CHOP,放疗和利图昔单抗维持治疗,获得完全缓解。10年后,患者发展为溃疡性浅表扩散黑色素瘤(Breslow厚度4.5 mm, pT4b),分期CT显示右侧腋窝淋巴结病变。活检证实滤泡性淋巴瘤复发。手术治疗包括广泛切除和前哨淋巴结活检,其中一个前哨淋巴结发现黑色素瘤转移,非前哨淋巴结确认FL。分子检测显示BRAFV600E突变。患者接受腋窝放疗后辅助BRAF/MEK抑制剂治疗。结论:随访6个月,影像学未见复发。这是第一例记录在案的同步III期BRAF突变的MM和FL,采用靶向BRAF/MEK抑制剂联合局部放疗治疗。成功的结果验证了这种连续的多学科方法,并强调了NHL幸存者皮肤病学监测的重要性。